NCT04508075View on ClinicalTrials.gov

Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

1,620

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

January 9, 2021

Study Completion Date

August 31, 2021

Conditions
SARS-CoV2 Infection
Interventions
BIOLOGICAL

SARS-CoV-2 vaccine (inactivated)

SARS-CoV-2 vaccine (inactivated) manufactured by Sinovac

BIOLOGICAL

Placebo

Placebo manufactured by PT. Bio Farma

Trial Locations (1)

Unknown

Hasan Sadikin Hospital/School of Medicine, Padjadjaran University, Bandung

Sponsors

Lead Sponsor

PT Bio Farma
All Listed Sponsors
collaborator

Faculty of Medicine Universitas Padjadjaran

UNKNOWN

collaborator

National Intitute of Health Research and Development, Ministry of Health Republic of Indonesia

UNKNOWN

collaborator

Sinovac Life Sciences Co., Ltd.

INDUSTRY

lead

PT Bio Farma

INDUSTRY